Intrommune Therapeutics Names Chief Operating Officer
25 mars 2021 09h10 HE
|
Intrommune Therapeutics
NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other...
Research Presentations at the 2021 Annual AAAAI Meeting Highlight Limitations of Current Food Allergy Treatments and Further Validates Intrommune Therapeutics’ Approach
12 mars 2021 09h30 HE
|
Intrommune Therapeutics
NEW YORK, March 12, 2021 (GLOBE NEWSWIRE) -- The clinical and scientific team of Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing patient-friendly treatments...
Intrommune Therapeutics Publishes Peanut Allergy and Immunotherapy Report
23 févr. 2021 12h00 HE
|
Intrommune Therapeutics
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly immunotherapy platform for the treatment of...
Intrommune Receives IND Clearance From U.S. Food and Drug Administration for INT301
04 févr. 2021 09h13 HE
|
Intrommune Therapeutics
NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies,...
Intrommune to Participate in BIO @ JPM During “J.P. Morgan Week 2021”
07 janv. 2021 17h35 HE
|
Intrommune Therapeutics
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, will...
It’s OFFICIAL: Huge AAFA Advocacy Victory! School-Based Allergies and Asthma Management Program Act, H.R. 2468 Becomes Law
05 janv. 2021 18h59 HE
|
Asthma and Allergy Foundation of America
Washington D.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Today the president signed H.R. 2468, the School-Based Allergies and Asthma Management Program Act into law. This bipartisan legislation will help...
AAFA Celebrates Major Advocacy Win! Congress Passes School-Based Allergies and Asthma Management Program Act, H.R. 2468
17 déc. 2020 19h13 HE
|
Asthma and Allergy Foundation of America
Washington D.C., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Today Congress passed H.R. 2468, the School-Based Allergies and Asthma Management Program Act. This bipartisan bill will help millions of U.S....
AAFA Praises U.S. House Passage of the FASTER Act
17 nov. 2020 21h34 HE
|
Asthma and Allergy Foundation of America
Washington D.C., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Today the House of Representatives passed H.R. 2117. Named the Food Allergy Safety, Treatment, and Research Act, it is easier known as the FASTER...
Intrommune Therapeutics Strikes Deal with Circuit Clinical®
20 oct. 2020 10h00 HE
|
Intrommune Therapeutics
NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Intrommune Therapeutics has announced an expanded partnership with Circuit Clinical, a leading Integrated Research Organization (IRO). Based on this deal,...
Recent Peer-Reviewed Publication Supports Immunotherapy for the Treatment of Food Allergies
08 oct. 2020 09h50 HE
|
Intrommune Therapeutics
NEW YORK, Oct. 08, 2020 (GLOBE NEWSWIRE) -- A recent publication in the journal Immunotherapy reviews a variety of immunotherapy platforms for the treatment of food allergies. The article,...